Episode 523 - Rodolfo Estrada, MD

Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients.

This Special Edition episode is sponsored by Liquidia.

Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com. 

YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. Learn more about the INSPIRE study.

Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: [email protected] Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @REstradaMD @UTHealthSA

IMPORTANT SAFETY INFORMATION
Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you:

• Have low blood pressure
  
• Have or have had bleeding problems
  
• Have asthma or chronic obstructive pulmonary disease (COPD)
  
• Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby
  
• Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other.

Especially tell your healthcare provider if you take:

• Medicines used to treat high blood pressure or heart disease
  
• Medicines that decrease blood clotting (anticoagulants)
  
• Water pills (diuretics)
  
• Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of YUTREPIA?

This product can cause serious side effects, including:

• Low blood pressure (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more.
• Bleeding problems. This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1–800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1–888–393–5732.